Hardy Reed LLC Sells 1,069 Shares of Thermo Fisher Scientific Inc. $TMO

Hardy Reed LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.0% in the first quarter, Holdings Channel reports. The fund owned 4,027 shares of the medical research company’s stock after selling 1,069 shares during the quarter. Hardy Reed LLC’s holdings in Thermo Fisher Scientific were worth $1,979,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.2%

Thermo Fisher Scientific stock opened at $522.38 on Monday. Thermo Fisher Scientific Inc. has a one year low of $403.36 and a one year high of $643.99. The stock has a market cap of $194.13 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock has a 50-day moving average of $473.17 and a two-hundred day moving average of $517.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective on the stock. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Weiss Ratings downgraded shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Morgan Stanley reissued an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $605.09.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.